ZA200509123B - N-(((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes - Google Patents

N-(((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes Download PDF

Info

Publication number
ZA200509123B
ZA200509123B ZA200509123A ZA200509123A ZA200509123B ZA 200509123 B ZA200509123 B ZA 200509123B ZA 200509123 A ZA200509123 A ZA 200509123A ZA 200509123 A ZA200509123 A ZA 200509123A ZA 200509123 B ZA200509123 B ZA 200509123B
Authority
ZA
South Africa
Prior art keywords
alkyl
phenyl
groups
halogen
independently
Prior art date
Application number
ZA200509123A
Other languages
English (en)
Inventor
Zandt Michael C Van
Fang Haiquan
Whitehouse Darren
Hu Shaojing
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of ZA200509123B publication Critical patent/ZA200509123B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200509123A 2003-04-14 2005-11-11 N-(((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes ZA200509123B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46310203P 2003-04-14 2003-04-14

Publications (1)

Publication Number Publication Date
ZA200509123B true ZA200509123B (en) 2007-04-25

Family

ID=33300037

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509123A ZA200509123B (en) 2003-04-14 2005-11-11 N-(((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes

Country Status (15)

Country Link
US (1) US20040248937A1 (es)
EP (1) EP1633354B1 (es)
JP (1) JP2006524248A (es)
KR (1) KR20050121732A (es)
CN (1) CN1794989A (es)
AT (1) ATE384526T1 (es)
AU (1) AU2004231106A1 (es)
BR (1) BRPI0409447A (es)
CA (1) CA2522080A1 (es)
DE (1) DE602004011511T2 (es)
EA (1) EA200501607A1 (es)
MX (1) MXPA05010937A (es)
NO (1) NO20054769L (es)
WO (1) WO2004092146A2 (es)
ZA (1) ZA200509123B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
KR20060006953A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
BRPI0511703B8 (pt) * 2004-06-04 2021-05-25 Merck Sharp & Dhome Corp composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
CN1993124A (zh) 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
JP2008518926A (ja) * 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
DE102006013957A1 (de) * 2006-03-27 2007-10-04 Bayer Healthcare Aktiengesellschaft Substituierte N-Benzyl-N-phenylbenzolsulfonamide
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
WO2012100734A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
RS55225B1 (sr) 2011-02-08 2017-02-28 Pfizer Modulator glukagon receptora
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
CN104884452A (zh) 2012-11-20 2015-09-02 沃泰克斯药物股份有限公司 用作吲哚胺2,3-二氧化酶的抑制剂的化合物
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
CN106661008A (zh) 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
BR112018015413A2 (pt) 2016-02-09 2018-12-18 Inventisbio Inc inibidores de indoleamina-2,3-dioxigenase (ido)
CN106632076B (zh) * 2016-09-20 2019-04-30 中国药科大学 4,6-二苯基嘧啶类化合物、其制备方法和医药用途
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR102606541B1 (ko) * 2021-04-23 2023-11-29 가천대학교 산학협력단 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US6677364B2 (en) * 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2260777C (en) * 1996-07-19 2006-06-13 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
PE20000127A1 (es) * 1997-12-22 2000-03-14 Novartis Ag Derivado de bencenosulfonamida
EP1077960A1 (en) * 1998-05-12 2001-02-28 American Home Products Corporation (2-acylaminothiazole-4-yl)acetic acid derivatives
MXPA01008606A (es) * 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
WO2001019830A1 (en) * 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
IL145756A0 (en) * 2000-02-05 2002-07-25 Vertex Pharma Pyrazole derivatives and pharmaceutical compositions containing the same
WO2001083464A1 (fr) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
AU2001248820A1 (en) * 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
EP1331224A4 (en) * 2000-09-29 2004-03-17 Shionogi & Co THIAZOLE AND OXAZOLE DERIVATIVES
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
WO2002036602A1 (fr) * 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10150172A1 (de) * 2001-10-11 2003-04-30 Morphochem Ag Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
EP1438044A1 (en) * 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
EP1453470A4 (en) * 2001-11-19 2006-05-17 Iconix Pharm Inc MODULATORS OF RHO C ACTIVITY
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
CA2474433A1 (en) * 2002-01-30 2003-08-07 Tularik Inc. Arylsulfonamidobenzylic compounds
DE60332738D1 (de) * 2002-07-30 2010-07-08 Merck Sharp & Dohme Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
CN100457730C (zh) * 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物

Also Published As

Publication number Publication date
EP1633354A2 (en) 2006-03-15
AU2004231106A1 (en) 2004-10-28
DE602004011511D1 (de) 2008-03-13
CN1794989A (zh) 2006-06-28
WO2004092146A3 (en) 2004-12-29
EP1633354B1 (en) 2008-01-23
NO20054769D0 (no) 2005-10-17
CA2522080A1 (en) 2004-10-28
WO2004092146A2 (en) 2004-10-28
BRPI0409447A (pt) 2006-04-18
KR20050121732A (ko) 2005-12-27
DE602004011511T2 (de) 2009-01-29
MXPA05010937A (es) 2005-11-25
JP2006524248A (ja) 2006-10-26
US20040248937A1 (en) 2004-12-09
NO20054769L (no) 2006-01-03
ATE384526T1 (de) 2008-02-15
EA200501607A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
ZA200509123B (en) N-(((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
US20060100251A1 (en) Substituted phenylalkanoic acids
US7582632B2 (en) Tri(cyclo) substituted amide compounds
JP6569792B2 (ja) ハロゲン置換へテロ環化合物
CN100506807C (zh) 作为gk活化剂的酰胺衍生物
US5710140A (en) Phenyl heterocycles as COX-2 inhibitors
US7524878B2 (en) Phenyl substituted carboxylic acids
EP2383263B1 (en) Novel thiazolidinedione derivative and use thereof
AU2004236247A1 (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1 B
JP2006517590A5 (es)
JP2005509616A (ja) チロシンホスファターゼに対する有機硫黄阻害剤
JP2008516999A (ja) 複素環式カルボニル化合物
BG63082B1 (bg) Фенилови хетероциклени съединения като инхибиторина циклооксигеназа-2
ZA200509631B (en) Subsituted carboxylic acids
US20130150413A1 (en) Benzisothiazol-3(1h)-one-5-sulfonyl derivatives as chemokine receptor modulators